Member Info for sadoldgit

A good not OTT read in link below.

Highlights importance if selectibuty of jak1 over other Jaks especially Jak2.

A very underestimated importance of no Jak2 activity detected along with no increase in creatinine levels detected in SAD & MAD dosing.

With regards to diseases that currently are treated with steroids there us an urgent need to find NSAID treatments.

The link below

https://pmc.ncbi.nlm.nih.gov/articles/PMC8098105/

The juggest

All the more important to achieve approval for long term use following toxicology studies.

Better safety than Breprocitinib with greater efficacy than Deucravacitinib.

Regards

Good morning C79

Thankyou for tge detailed response with regards to valuations.

Sareum been nigh pushed into financial failure by RF a while back and you have put through a very valid valuation with the help of AI that run into the billions.

My belief is we certainly have a cleaner safety profile but may not have such a great efficacy in certain indications.

However, escalation to a higher dose may resolve this issue dependant on dise limiting toxicity of course.

In essence how effective our very small by comparison of Jak1 to Breprocitinib?

Adverse effects are similar to placebo.

No Jak2 activity detected.

Jak 1 showing no adverse events.

As Tim stated a while back in that they believe they have the optimum amount of Jak1 content

In essence there is a playoff here with efficacy against adverse reactions.

DM or dermatomyositis more than likely will respond better to higher Jaki content.

All in all very promising dnd if we are looking st valuations, Tim and co will be looking st valuations and pharma will be looking at commercialisation value and uhe least expensive way they can obtain.

Ourselves do not know what other current and upcoming competition we face. Tim snd Co will have much greater knowledge of this.

Regards and great input C79

Peer review.

Yes it would be great to see a peer review on 1801 if only just to give us some feed back on development.

Those who we may be in discussions with will know more. Further to the point Tim and Steve did dwell on factors regarding 1801 especially with regards to confidentiality and what our competitors could gain.

C79 bless him has put some decent posts in and so has Potnak although we do seldom agree on much but ball park figures not tgst much out.

C79 and several billion on valuation/ revenue.

Breprocitinib is not going to be used in Psoriasis as basically not safe enough. Too many off target effects.

So although not as far developed we are looking at being better on Breprocitinib with regards to safety and have greater efficacy than Deucravacitinib.

How wide us the grey line here?

Figures of 1 to 4 billion turnover per annum forecast for Brepro and Deucra respectively.

We sit between the two surely on 1801 alone ?

Then we have 1802 and potentially far higher commercialisation value with 1803 albeit early stage but fo have compounds thst have shown meaningful brain penetration.

I did put a figure of 400 million at phase 2 on 1801 3 years ago.

I dont think far out as the real importance is the safety profile over efficacy in Psoriasis and of almost equal importance being safer than the rest in areas of unmet need.

Biggest threat is dawdling about and waiting for potentially donating better to come out before we are commercialised.

One thing for sure is we should kot be sitting at less than 100 million market cap at this stage.

Regards have a good weekend all.

Riverfort Global Opportunities PLC

What they do: Riverfort is a specialist investor that provides a range of financial solutions to public companies, particularly small and mid-cap public companies listed on exchanges such as the London Stock Exchange.

Services: They are known for their innovative financing solutions, including debt and equity solutions, to help companies grow and execute their strategies.

Peel Hunt

What they do: Peel Hunt is a UK investment bank with a focus on advisory services for corporate clients.

Services: Their expertise includes equity capital markets, mergers and acquisitions (M&A), investor relations, and corporate broking.

Structure: The firm was originally founded by Charles Peel and Christopher Holdsworth Hunt in 1989 and is now an independent UK investment bank with offices in London, Copenhagen, and New York.

Summary of Connection

There is no evidence of a direct business partnership, merger, or acquisition linking the two entities.

It's possible they have worked with each other on a deal-by-deal basis, as Riverfort is a capital provider and Peel Hunt provides advisory and capital markets services. However, this would be a client-service provider relationship, not a structural one.

Yes good we are out. If not feel we would be up to our neck. Riverboat Global were instrumental in the decline of Sareum, Genedrive and deceral others.

Cause funds in issue of new aggressive, flood the market and issue more shares to make up for the shortfall furhere devaluating the company.

Then company goes into administration of which RF own all tge shares.

Then they can sell on. Nigh as mercenary as Blackrock.

CNS developments should come good and of course tge identification od one compound that is showing very promising in early pre clinical.

Sareum have never ever have over emphasised on their compound attributes.

Positive slant on timelines a definite maybe

Regards

Good result HbD.

I would not agree entirely.

A 4 month tox study that starts at early in the New Year does not equate to end of year.

Neither can l recall by end of year at the AGM.

Regards

Most notable and in depth read is ftom the Journal of Thoracic Oncology 2019.

One of the authors was John V Heymach who was also an advisor to GSK.

You can scroll down a tad to results and quite impressive I find

https://www.jto.org/article/S1556-0864(19)30692-6/fulltext

Regards

Thanks for that HbD.

I were looking at the lines of a PD-1 inhibitor along the lines of Mercks Kertruda.

That goes off patent 2027 I think.

Method of application has changed fron IV Zto under the skin.

Question is does the intravenous patent expire or can it be protected?

We are looking at SCLC here and in triple combo 737 LDG and PD-1 inhibitor was described as remarkable.

For lovers of AI

"AI Overview

+3

Yes, companies manufacturing generic drugs are increasingly interested in combination therapies, especially complex generics that are harder to replicate and offer higher-value opportunities, although challenges exist in collaborating with different manufacturers due to anti-trust concerns. This strategic pivot allows generic companies to move beyond simple low-cost drugs into more innovative, profitable niches within the market, such as advanced formulations and drug-device combinations. '

Regards

It vould be patented in triple combo with a programmed death ligand inhibitor.

In my opinion there us a degree of impatience here and thst includes myself.

What us nut going to happen is some one sees 737 back in the window and make an offer to buy.

A minimum of 6 months.

That l were told a few years back by a very established solicitor who dealt in company law.

Depending on the complexity he said you could be looking st a year snd maybe 18 months.

We have had it back 5 months.

Small cell lung cancer typically 15% of all lung cancers and is very aggressive.

Midt treatments destroyed the cancer cell but fo nothing to control the production of duplicate cancer cells

Personally l would like to see 747 sold on and if a ball park figure of a couple of million up front with several millions in milestones later.

Take into condideration jow long it will take to analyse the 235 Gb of data. Sareum looking at it first then interested party.

Then they need negotiate terms and conditions informally.

Contract drawn up with terms conditions and milestones.

You looking at 75k minimum solicitors fees in my opinion maybe double that

We msy hear of something next month but doubt it.

It would have to be in combo therapy and that us where tge difficulty arises.

As an idea a PD-1 inhibitor coming to the end of its patent life and hence then a genetic drug then maybe the manufacturer of the genetric drug could take on 737 in combo.

Would Merck fear that?

Regards

Since as Keytruda generated 8 billion dollars in the 2nd quarter

Merck must be aware of chk1 inhibitor in combo effectiveness eith PD-1 and LDG.

An excerpt from 2019 T Sen

'Conclusions: Given that anti-PD-L1/anti-PD-1 drugs have recently been approved as monotherapy and in combination with chemotherapy for the treatment of SCLC, and that the SRA737 + low dose gemcitabine regimen is currently in clinical trials for SCLC and other malignancies, our preclinical data provide a strong rational for combining this regimen with inhibitors of the PD-L1/PD-1 pathway.'⁸

Https://www.fiercepharma.com/pharma/merck-scores-fda-approval-subcutaneous-keytruda

From April RNS

A fair bit of data to go through for 737.

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Sareum has now received the full clinical dataset for SRA737, following the termination of its licensing agreement with a US-based partner in December 2024. This includes the Trial Master File and all associated documentation - these data amount to approximately 235Gb. With full operational control attained, Sareum is now positioned to conduct a comprehensive review of the programme's potential.

Strategic options under consideration include re-licensing the asset or advancing it in-house with or without a partner. The former licensee has expressed continued confidence in SRA737's clinical profile, which Sareum believes will support potential future partnering discussions. A decision on the optimal path forward will be made in the context of broader pipeline priorities including the opportunity to enhance shareholder value through partnering or re-licensing.

I understand your thinking Steve196.

Ftom the AGM last year you roild get the impression that all will progress.

Looking for an on licence and if offer was enough a take over

Early in the Ney year commence toxicology study.

I asked when is it likely to start.

In the RNS they use the term initiate

You put a key in the ignition to start a car

The key is the initiation process

If your battery is flat the car will not start.

It would have been better to have waited a few days and then released a statement to say the toxicology study has commenced.blsh di bush di blah.

I have faith in the compounds

We should here within next 2 to 3 weeks of st least preliminary results.

How high fid they dose at ?

Have they established sn MTD

Any signs of toxicity in liver?

Any signs of kidney damage ?

On top of thst and most importantly many happy returns of the day to you. I will raise my glass to you.

Regards

Tend to agree eith most of your pist Potters but l am of the firm opinion thst the importance of the toxicology long term testing is very relevant yo safety.

Basically you will have a dual Tyk2 Jak1 inhibitor with no restrictions on use if all goes well.

If you don't think this is the case then why was Sotyktu 4 billion dollars. It's efficacy is not thst good

Failed dismally in UC whereby they achieved better results with tge placebo.

A pharna can trial this in any indication they see fit without fear of safety issues and if all goes as expected use as a treatment for as long as tgey like.

Biggest competitor in Auto immune in dome indications such as UC or CD is likely to be 1802 as UC and CD have a nasty habit if leading to cancer at later stages.

Sareum need put the hammer down.

Whst is 2nd priority?

1802 or 1803

Which of these are they focused on?

An advantage of course if the attacks is that it dies hive Sareum money and extends the cash runway a tad.

Over all l would say Sareum.would like a takeover, but as Tim M said if the right price were offered.

They can't make a formal now as safety of 2891 not confirmed for long term use. Simple as that.

As for current value we are around 70% undervalued and much more on satisfactory long term toxicology results.

Regards to all

Yes in reality very little negative affect on SP.

It may well be as PCS1954 suggested that buying of the warrants may come into play.

It may just be me being a tad negative.

With regards to a partnership or on licence it is far better to have some money in the coffers.

For a takeover also helpful. Removes the measures of desperation implied by lack of funds in any negotiation.

Afternoon PCS1954.

Tim is a Scientist whilst l have only been here 13 years l do realise that Tim has been CEO for nigh 20 years.

Scientists do not make good salesman.

I know some salesman who could sell sand to the Arabs. One of them has as sold sand for building.

A salesman will sell something for a price.

A scientist by his very nature tend not to be flexible or compromise.

Tge remark 4 years back thst if somebody wanted both compounds they would have to osy the price

.

This was an interview with the smooth talking Aussie Andrew Scott. Primarily about BMS Deucravacitinib and 1801,1802.

If they want both they will have to pay.

My approach would have been if a company wants both then l am sure we could come to a mutually beneficial to both parties agreement.

I am if the firm opinion tgst Tim is of the take it or leave it character. No movement no compromise.

Absolutely excellent attitude for a scientist .

No compromise on safety or efficacy, both will be achieved hence why our 1801 has knocked the spots off of Breprocitinib for one with regards safety profile. Breptocitinib discontinued in psoriasis. Perhaps it was formulated by a wannabe salesman.

Good salesman are hard to find.

I am sure the smooth talking Aussie on proactive investors would make a great salesman. Has all the attributes, charm, charisma and the ability to control the conversation.

The old sales technique of feel, felt and found.

RF global proved disastrous for Sareum.

In essence the idea was good. You raise money by the release of shares. Very little harm should be done if tjey are trickled back onto the market.

However they were not trickled back onto the market the market were flooded. Ftom.around a pound a share share they were pushed down to around 15p in around 8 months.

RF were without doubt trying to sink Sareum.

Push them in to administration and then RF global own the company.

Rf global can now sell companies the long awaited reverse takeover was achieved months and months back.

The question remains here is should a CEO remain as CEO after selecting such a route without assessing the downside?

On LinkedIn where the RF global site exists there was Tim Mitchells little red heart showing on the site. Put there around the same time as tge deal was struck.

Somebody in a position as CEO needs to have the ability to act like a Salesman and at the same time be extremely astute as to yhe antics and promises of financial institutions.

A further question here.

Had the current long term toxicology studies been carried out before the clinical trial application would the application then been approved?

I am not slating Tim. It does need someone st the helm who is flexible, knowledgeable and extremely astute.

With regards to great expectations l have set very high expectations from the company.

You msy ask, what the Dickens am l on about.

Having a couple of pints of draft Abbot now.

Enjoy your fish and chi

I were thinking the same myself HbD.

However. You could sell some now and gain twice as many bias the warrants.

The institutional investor msy be heading down this path.

Regsrds